SPECT imaging evaluation of 111indium-chelated cetuximab for diagnosing EGFR-positive tumor in an HCT-15-induced colorectal xenograft | Zendy

Bin-Bin Shih | Zendy; Yi-Fang Chang | Zendy; ChunChia Cheng | Zendy; Hao-Jhih Yang | Zendy; KangWei Chang | Zendy; Ai-Sheng Ho | Zendy; Hua-Ching Lin | Zendy; ChunNan Yeh | Zendy; ChunChao Chang | Zendy

Open Access

SPECT imaging evaluation of 111indium-chelated cetuximab for diagnosing EGFR-positive tumor in an HCT-15-induced colorectal xenograft

Author(s) -

Bin-Bin Shih,

Yi-Fang Chang,

ChunChia Cheng,

Hao-Jhih Yang,

KangWei Chang,

Ai-Sheng Ho,

Hua-Ching Lin,

ChunNan Yeh,

ChunChao Chang

Publication year - 2017

Publication title -

journal of the chinese medical association

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.535

H-Index - 42

eISSN - 1728-7731

pISSN - 1726-4901

DOI - 10.1016/j.jcma.2017.02.010

Subject(s) - cetuximab , medicine , colorectal cancer , biodistribution , epidermal growth factor receptor , monoclonal antibody , cancer research , cancer , oncology , antibody , in vivo , immunology , biology , microbiology and biotechnology

Epidermal growth factor receptor (EGFR) overexpressed in colorectal cancer (CRC) is a tumor target for developing the anti-tumor theranostic agents. Cetuximab, an anti-EGFR monoclonal antibody against EGFR-positive tumors, inhibits cell proliferation and growth was labeled with radioactive 111 indium ( 111 In) in this study for diagnosing EGFR-positive CRC. The aim of this study was to evaluate the efficacy of noninvasive nuclear imaging agen 111 In-cetuximab and investigate the biological distribution of 111 In-cetuximab in the HCT-15-induced EGFR-positive CRC tumor xenografts.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research